Long-term results after resection for bone sarcoma pulmonary metastases
Carlos E. García Franco (a), Wenceslao Torre (a), Akiko Tamura (a), Francisco Guillén-Grima (b), Mikel San-Julian (c), Salvador Martin-Algarra (d) and Francisco J. Pardo (e)
(a) Department of General Thoracic Surgery, Clinica Universidad de Navarra, Pamplona, Spain
(b) Department of Preventive Medicine, Clinica Universidad de Navarra, Pamplona, Spain
(c) Department of Orthopedic Surgery, Clinica Universidad de Navarra, Pamplona, Spain
(d) Department of Medical Oncology, Clinica Universidad de Navarra, Pamplona, Spain
(e) Department of Pathology, Clinica Universidad de Navarra, Pamplona, Spain
Magazine: European Journal of Cardio-Thoracic Surgery
Date: May 1, 2010Preventive Medicine [SP] Orthopedic Surgery and Traumatology [SP] Thoracic Surgery Pathological Anatomy [SP] Medical Oncology
Pulmonary metastases from bone sarcomas occur in approximately 40% of the cases. The combination of both chemotherapy and surgical resection is currently the standard treatment options for these patients. We aim to study the influence of different prognostic factors on long-term survival.
We reviewed the prognostic factors and survival rate in 52 consecutive patients with pulmonary metastases from bone sarcomas. All of them were previously treated with chemotherapy and submitted to metastasectomy at our institution from 1996 to 2006. Clinical and demographic variables, related to the primary tumour as well as to the pulmonary metastases, and treatment procedures were registered. Univariate (log-rank) and multivariate (Cox regression) analysis were carried out to identify significant prognostic factors related to overall survival. Five-year survival rates were estimated using Kaplan-Meier methods.
Median follow-up was 28 months. Follow-up duration ranged 7-148 months; the median survival was 27 months. As many as 31% of the patients were alive without disease, 3% were alive with disease, 64% died of disease while 2% died from other causes. Complete resection was achieved in 49 cases (94%). The overall 3- and 5-year survival rates were 43% and 31%, respectively. Univariate analysis showed (1) disease-free interval between treatment of the primary bone tumour and first lung metastasectomy (DFI) and (2) disease-free interval between first and second lung surgery (DFI2) as prognostic factors. Gender, primary site, histology of primary tumour, surgical approach, number of lung nodules, type of lung resection and re-do lung surgery did not have a significant impact on survival.
The long-term survival after bone sarcoma lung metastasectomy is encouraging. In our series, DFI and DFI2 were identified as the only prognostic factors.
CITATION Eur J Cardiothorac Surg. 2010 May;37(5):1205-8
you maybe interested
The Clínica is the greater private hospital with technological equipment of Spain, all in a single center.
The professionals of the Clínica perform continuous research and training, always to the benefit of the patient.
Learn why we are different from other healthcare centers. Quality, speed, comfort and results.